/DAWN
DAWN Stock - Day One Biopharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$9.24-7.32%
$0.73 (-7.32%) • Dec 19
89
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.95
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+181.4%upside
Target: $26.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DAWN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.15 – $9.33
TARGET (TP)$26.00
STOP LOSS$8.50
RISK/REWARD1:22.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.28
52W High$13.53
52W Low$5.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $131.16M | N/A | N/A | N/A | N/A |
| Gross Profit | $125.88M | $-383,000 | $-531,000 | $-199,000 | $-155,000 |
| Gross Margin | 96.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-217,270,000 | $-206,064,000 | $-146,909,000 | $-72,743,000 | $-13,782,000 |
| Net Income | $-95,496,000 | $-188,917,000 | $-142,181,000 | $-70,645,000 | $-40,507,000 |
| Net Margin | -72.8% | N/A | N/A | N/A | N/A |
| EPS | $-1.02 | $-2.37 | $-2.02 | $-1.14 | $-0.65 |
Company Overview
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
88%
Hold / Neutral
0%
Sell / Underperform
1
13%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$32
Average Target
↑ 244.2% Upside
Now
$9
Low
$32
Average
$45
High
Based on 10 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $25 |
| October 9th 2024 | Needham | Reiterated | Buy | $33← $32 |
| August 1st 2024 | BofA Securities | Upgrade | Buy | $24← $11 |
| April 24th 2024 | Needham | Reiterated | Buy | $33← $30 |
| April 25th 2023 | BofA Securities | Downgrade | Underperform | $9← $34 |
| February 8th 2023 | CapitalOne | Initiation | Overweight | $40 |
| February 3rd 2023 | Oppenheimer | Initiation | Perform | - |
| December 15th 2022 | H.C. Wainwright | Initiation | Buy | $35 |
| December 14th 2022 | Needham | Initiation | Buy | $40 |
| December 5th 2022 | Goldman | Initiation | Buy | $45 |
| December 1st 2022 | BofA Securities | Initiation | Buy | $34 |
Earnings History & Surprises
DAWNBeat Rate
44%
Last 18 quarters
Avg Surprise
-74.2%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.19
Q4 2025
EPS Surprise History
Q1 24
-12.3%
$-0.64vs$-0.57
Q2 24
-7.5%
$-0.72vs$-0.67
Q3 24
+92.5%
$-0.05vs$-0.67
Q4 24
+192.7%
$0.38vs$-0.41
Q1 25
-97.1%
$-0.69vs$-0.35
Q2 25
+23.9%
$-0.35vs$-0.46
Q3 25
+17.1%
$-0.29vs$-0.35
Q4 25
+31.8%
$-0.19vs$-0.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | $-0.18 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.28 | $-0.19 | +31.8% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.35 | $-0.29 | +17.1% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.46 | $-0.35 | +23.9% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.35 | $-0.69 | -97.1% | ✗ MISS |
Q4 2024 | Oct 30, 2024 | $-0.41 | $0.38 | +192.7% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $-0.67 | $-0.05 | +92.5% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.67 | $-0.72 | -7.5% | ✗ MISS |
Q1 2024 | Feb 26, 2024 | $-0.57 | $-0.64 | -12.3% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.60 | $-0.54 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.60 | $-0.61 | -1.7% | ✗ MISS |
Q2 2023 | May 1, 2023 | $-0.60 | $-0.59 | +1.7% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.57 | $-0.56 | +1.8% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.53 | $-0.53 | 0.0% | = MET |
Q3 2022 | Aug 4, 2022 | $-0.49 | $-0.60 | -22.4% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.39 | $-0.48 | -23.1% | ✗ MISS |
Q1 2022 | Mar 7, 2022 | $-0.36 | $-0.36 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-0.28 | $-0.33 | -17.9% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.31 | $-5.04 | -1525.8% | ✗ MISS |
Q2 2021 | May 27, 2021 | — | $-0.56 | — | — |
Latest News
Watching Day One Biopharmaceuticals; Shares Spike Higher, Traders Circulate Unconfirmed M&A Rumors
📈 PositiveBenzinga•Dec 8, 2025, 04:00 PM
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $25 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 05:29 PM
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $16 Price Target
📈 PositiveBenzinga•Nov 24, 2025, 02:48 PM
Day One Biopharma Announces 3-Yr Results From OJEMDA Pivotal Phase 2 FIREFLY-1 Trial In Oral Presentation At 2025 SNO Annual Meeting
📈 PositiveBenzinga•Nov 24, 2025, 01:03 PM
Mersana Therapeutics shares are trading higher after the company announced it will be acquired by Day One Biopharmaceuticals.
📈 PositiveBenzinga•Nov 13, 2025, 02:02 PM•Also:
Day One Biopharmaceuticals shares are trading lower after the company anounced it will acquire Mersana Therapeutics.
📉 NegativeBenzinga•Nov 13, 2025, 01:51 PM•Also:
Day One Biopharmaceuticals Agrees To Acquire Mersana Therapeutics For $25 Per Share In Cash Plus One Non-tradable CVR Up To An Aggregate Of $30.25 Per CVR In Cash
📈 PositiveBenzinga•Nov 13, 2025, 11:05 AM•Also:
Day One Biopharmaceutical Announced It Will Present New Ojemda Durability And Clinical Stability Data From The Registrational Firefly-1 Study At The 30Th Annual Meeting & Education Day Of The Society For Neuro-oncology (Sno)
📈 PositiveBenzinga•Nov 10, 2025, 12:13 PM
JP Morgan Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $27
📈 PositiveBenzinga•Nov 7, 2025, 07:42 PM
Day One Biopharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and Piper Sandler maintained an Overweight rating on the stock and raised its price target from $25 to $26.
📈 PositiveBenzinga•Nov 5, 2025, 05:29 PM
Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $26
📈 PositiveBenzinga•Nov 5, 2025, 03:44 PM
Day One Biopharmaceutical Q3 EPS $(0.19) Beats $(0.29) Estimate, Sales $39.795M Beat $38.200M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:01 PM
Frequently Asked Questions about DAWN
What is DAWN's current stock price?
Day One Biopharmaceuticals, Inc. (DAWN) is currently trading at $9.24 per share. The stock has moved -7.32% today.
What is the analyst price target for DAWN?
The average analyst price target for DAWN is $26.00, based on 1 analyst.
What sector is Day One Biopharmaceuticals, Inc. in?
Day One Biopharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DAWN's market cap?
Day One Biopharmaceuticals, Inc. has a market capitalization of $0.95 billion, making it a small-cap company.
Does DAWN pay dividends?
No, Day One Biopharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
ATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
RZLT
Rezolute, Inc.
$1.77
Mkt Cap: $0.2B
TYRA
Tyra Biosciences, Inc.
$25.51
Mkt Cap: $1.4B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to DAWN for comparison